Rucaparib
clovis
['ovarian', 'rucaparib', 'gyn']
patients with newly diagnosed ovarian cancer with or without a high risk of progression experienced a pfs benefit from treatment with maintenance rucaparib compared with placebo regardless of molecular characteristics. #gyncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.